WO2002005802A1 - Method of fundamentally treating common cold - Google Patents

Method of fundamentally treating common cold Download PDF

Info

Publication number
WO2002005802A1
WO2002005802A1 PCT/JP2001/005225 JP0105225W WO0205802A1 WO 2002005802 A1 WO2002005802 A1 WO 2002005802A1 JP 0105225 W JP0105225 W JP 0105225W WO 0205802 A1 WO0205802 A1 WO 0205802A1
Authority
WO
WIPO (PCT)
Prior art keywords
common cold
upper respiratory
respiratory tract
treatment
drug
Prior art date
Application number
PCT/JP2001/005225
Other languages
French (fr)
Japanese (ja)
Inventor
Saburo Yasuda
Original Assignee
Saburo Yasuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saburo Yasuda filed Critical Saburo Yasuda
Priority to AU2001274552A priority Critical patent/AU2001274552A1/en
Publication of WO2002005802A1 publication Critical patent/WO2002005802A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to a method for treating a common cold and a method for treating hay fever, and belongs to the pharmaceutical industry. Means for Solving the Problems As a means for solving the problems, the concentration of the drug to be inhaled is increased to a level that causes the upper respiratory mucosal cells to malfunction physiologically.
  • Chemicals include monohydric alcohols (ethanol, butyl alcohol, menthol, etc.) Volatile sulfides (aryl sulfide, etc.) Volatile acid / base compounds (hydrochloric acid, ammonia, etc.) Trihalomethane (cloguchi form, etc.) Volatile compounds can be considered that cause any upper respiratory mucosal cells to physically malfunction.
  • Cold is an inflammation of the mucous membrane of the respiratory tract, mostly caused by a virus.
  • This cold virus does not have DN ⁇ and attaches to the upper respiratory tract mucosal cells of living mammals and birds, enters the cells and begins to proliferate. Thus, if the upper respiratory mucosal cells become physically dysfunctional, the cold virus cannot multiply.
  • the cold virus loses its activity as an organism within a few hours at body temperature, so it can treat a cold such as influenza fundamentally.
  • the radical treatment for a cold according to the present invention is effective in principle for all of the 230 types of cold viruses. Influenza detected in Hong Kong It is also effective in principle for Enza AH type 5 (very toxic and difficult to produce vaccines; one out of three die).
  • the inhalant of a hydrocarbon enzyme inhibitor is a drug powder, it cannot be inhaled in a sustained-release manner. Therefore, except during inhalation, it is washed away by the mucus on the surface of upper respiratory mucosal cells, and the effect is reduced by half. Enzyme inhibitors are concerned about side effects when used in combination with other drugs (such as botanicals). This treatment can be said to be the most effective cold treatment for influenza AH5, for which measures are urgent.
  • the upper respiratory tract mucosal cells can always be physiologically dysfunctional and the drug can be converted into mucus, compared to the influenza treatment method described above, in which the drug powder is inhaled at regular intervals. It is effective because it is not washed away. It can be inhaled with respiration even to elderly people and infants who are likely to die in Influenza.
  • the present invention discloses, for the first time in the world, a method for completely treating all viral colds.
  • Example Menthol is considered to be suitable as the drug used because of its ease of handling, low cost, and harmlessness, but monohydric alcohol having anesthetic properties (such as ethyl alcohol) may be used.
  • the cold such as influenza, parainfluenza, adeno, etc.
  • the cold such as influenza, parainfluenza, adeno, etc.
  • radical treatment can be performed.
  • regeneration of upper respiratory mucosal cells It takes several days, so even if the fever goes down, it will last for a few days, but the general malaise has been removed. Runny nose stops while inhaling hay fever.
  • Sustained-release inhalation is effective and should be worn on a mask. For how to attach to the mask, refer to past patent and utility model applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Although masks with the sustained release of menthol have been marketed for the symptomatic treatment of common cold and hay fever, fundamental treatment cannot be established thereby. By using these marketed masks, it is impossible to inhale a drug at such a high concentration as causing a slight pain in the upper respiratory tract mucosa. Inhalation of a drug vapor at such a high concentration as causing a slight pain in the upper respiratory tract mucosa causes physiological dysfunction of upper respiratory tract mucosa cells and thus inhibits the proliferation of common cold viruses. Since common cold viruses are inactivated within several hours at the body temperature, common cold including influenza can be completely treated (defervescence) thereby. This treatment method is efficacious against all common cold viruses over 230 types. Thus, an efficacious method of fundamentally treating all types of viral common cold is disclosed for the first time in the world. Moreover, the absorption of antigens such as pollen can be inhibited thereby. Thus, a method of temporarily treating hay fever by inhibiting the formation of immune complexes is also provided.

Description

明 細 書 産業上の利用可能性 本発明は、 風邪の根本的な治療方法や、 花粉症の治療方法に関し、 医薬産業 分野に属する。 課題を解決するための手段 課題を解決するための手段として、 吸入すべき薬剤の濃度を上気道粘膜細胞 を生理的に機能不全させる程度の濃度まで上げる。  TECHNICAL FIELD The present invention relates to a method for treating a common cold and a method for treating hay fever, and belongs to the pharmaceutical industry. Means for Solving the Problems As a means for solving the problems, the concentration of the drug to be inhaled is increased to a level that causes the upper respiratory mucosal cells to malfunction physiologically.
薬剤としては、 1価のアルコール （エタノール · ブチルアルコール · メント ール等） 揮発性の硫化物 （硫化ァリル等） 揮発性の酸 ·塩基化合物 （塩酸 · ァ ンモニァ等） トリハロメタン （クロ口ホルム等） あらゆる上気道粘膜細胞を生 理的に機能不全させる揮発性化合物が考えられる。 使用可能薬剤は無数に有り その全てに適正な薬剤濃度を記載することは不可能だが、 メントール使用の場 合、 上気道粘膜に軽い痛みを覚える程度の高濃度であれば、 風邪を根本的治療 できると考えてよい。  Chemicals include monohydric alcohols (ethanol, butyl alcohol, menthol, etc.) Volatile sulfides (aryl sulfide, etc.) Volatile acid / base compounds (hydrochloric acid, ammonia, etc.) Trihalomethane (cloguchi form, etc.) Volatile compounds can be considered that cause any upper respiratory mucosal cells to physically malfunction. There are innumerable drugs available, and it is impossible to list the correct drug concentration for all of them.However, when using menthol, if the concentration is high enough to cause slight pain in the upper respiratory tract mucous membrane, a radical treatment for colds You can think that you can do it.
作用 ·効果 風邪とは、 気道粘膜での炎症を言い、 大部分はウィルスにより発病する。 この風邪ウィルスは D N Αを持たず、 生きた哺乳類 · 鳥類の上気道粘膜細胞 に付着し、 細胞内に進入して増殖を始める。 このため、 上気道粘膜細胞が生 理的に機能不全になると、 風邪ウィルスは増殖できない。 風邪ウィルスは体 温では数時間で生命体としての活性を失うので、 インフルエンザ等の風邪を 根本的に治療できる。 本発明にかかる風邪根本治療法は、 2 3 0種に及ぶ全 ての風邪ウィルスに、 原理的に有効である。 又、 香港で検出されたインフル ェンザ A H 5型 （極めて毒性が強くワクチンの製造が困難 · 3人に 1人が死 亡） にも、 原理的に効果を示す。 特にインフルエンザ A H 5型で死亡例が多 い寝たきり老人 · 乳幼児には、 今年発売された米国のダラクソ社製のシアル 酸を切り離す酵素を阻害する炭化水素の吸入薬 （回復が 2 日程度早い効果） が使えないので、 マスクによる吸入ができる本治療法は有効である。 Action · Effect Cold is an inflammation of the mucous membrane of the respiratory tract, mostly caused by a virus. This cold virus does not have DN 、 and attaches to the upper respiratory tract mucosal cells of living mammals and birds, enters the cells and begins to proliferate. Thus, if the upper respiratory mucosal cells become physically dysfunctional, the cold virus cannot multiply. The cold virus loses its activity as an organism within a few hours at body temperature, so it can treat a cold such as influenza fundamentally. The radical treatment for a cold according to the present invention is effective in principle for all of the 230 types of cold viruses. Influenza detected in Hong Kong It is also effective in principle for Enza AH type 5 (very toxic and difficult to produce vaccines; one out of three die). Particularly for bedridden elderly and infants who have died of influenza AH type 5 inhaled, this year's release of Daraxo, a US-based carbohydrate inhaler that inhibits the enzyme that cuts off sialic acid (recovery effect is about two days faster) This treatment, which can be inhaled with a mask, is effective because it cannot be used.
炭化水素系酵素阻害剤の吸入薬は薬剤粉であるので徐放的に吸入きないの で、 吸入時以外は上気道粘膜細胞表面の粘液により流され、 効果は半減する 。 酵素阻害剤は他の薬剤 （坊癌剤等） と併用した時の副作用が心配で有る。 本治療法は、 対策が急がれるィンフルェンザ A H 5型に最も有効な風邪治療 法と言える。  Since the inhalant of a hydrocarbon enzyme inhibitor is a drug powder, it cannot be inhaled in a sustained-release manner. Therefore, except during inhalation, it is washed away by the mucus on the surface of upper respiratory mucosal cells, and the effect is reduced by half. Enzyme inhibitors are worried about side effects when used in combination with other drugs (such as botanicals). This treatment can be said to be the most effective cold treatment for influenza AH5, for which measures are urgent.
又、 マスクに装着する形式を取ることができるので、 上記に示した薬剤粉 を定時に吸入するインフルエンザ治療法より、 常時上気道粘膜細胞を生理的 に機能不全させることができ、 薬剤が粘液に流されないので効果的である。 ィンフルェンザで死亡し易い老人 ·乳幼児にも、 呼吸とともに吸入させるこ とができる。 本発明は、 世界で初めて、 全ての.ウィルス性の風邪を完全に根 本治療する方法を開示したものである。  In addition, since it can take the form of being worn on a mask, the upper respiratory tract mucosal cells can always be physiologically dysfunctional and the drug can be converted into mucus, compared to the influenza treatment method described above, in which the drug powder is inhaled at regular intervals. It is effective because it is not washed away. It can be inhaled with respiration even to elderly people and infants who are likely to die in Influenza. The present invention discloses, for the first time in the world, a method for completely treating all viral colds.
さらに、 花粉等の坑原物質の吸収も阻害されるため、 ィムノコンプレック スの発生を防ぎ花粉症を時限的に治療する。 即ち、 本治療法を実施している 間は発熱 ·鼻水等を治療する。  In addition, the absorption of pollen and other antimicrobial substances is also inhibited, so the occurrence of imnocomplex is prevented and hay fever is treated in a timely manner. That is, fever, runny nose, etc. are treated during the implementation of this therapy.
実施例 使用薬剤として、 扱い安さ ·低コスト · 無害性から、 メントールが適当と考 えられるが、 麻酔性を有する 1価のアルコール （エチルアルコール等） でも よい。 Example Menthol is considered to be suitable as the drug used because of its ease of handling, low cost, and harmlessness, but monohydric alcohol having anesthetic properties (such as ethyl alcohol) may be used.
上気道粘膜に軽い痛みを覚える程度の高濃度のメントール蒸気を徐放的に 吸入すると、 インフルエンザ · パラインフルエンザ · アデノ等の風邪を 8時 間程で解熱 ·根本治療できる。 咳を伴う風邪では， 上気道粘膜細胞の再生に 数日かかるので、 熱が下がっても、 数日間晐がでるが、 全身倦怠感は取れて いる。 花粉症も吸入している間は鼻水が止まる。 徐放的に吸入すると、 効果 的であり、 マスクに装着する形式が望ましい。 どの様にマスクに装着するか については、 過去の特許 ·実用新案出願を参考にするとよい。 風邪の初期に 吸入すればなお効果的であり、 上気道粘膜細胞に異常を感じた時、 又は、 鼻 水が出始めた時であれば、 低濃度のメントール蒸気でも根本治療できるが、 これ以後 （熱がでてから） は上気道粘膜に軽い痛みを覚える程度の高濃度の メントール蒸気を徐放的に吸入しなければ、 根本治療できない。 このことか ら、 卵酒は前述の原理を利用したものであるが極めて初期の風邪にしか利か ない。 By inhaling the menthol vapor at a high concentration enough to cause slight pain to the upper respiratory mucosa, the cold such as influenza, parainfluenza, adeno, etc. can be alleviated in about 8 hours, and radical treatment can be performed. For colds with cough, regeneration of upper respiratory mucosal cells It takes several days, so even if the fever goes down, it will last for a few days, but the general malaise has been removed. Runny nose stops while inhaling hay fever. Sustained-release inhalation is effective and should be worn on a mask. For how to attach to the mask, refer to past patent and utility model applications. It is still effective if inhaled at the beginning of a cold, and if you feel abnormalities in the upper respiratory mucosal cells, or when you have a runny nose, you can use a low concentration of menthol vapor to cure the disease. (After fever), radical treatment cannot be performed unless menthol vapor is inhaled at a high concentration that causes mild pain in the upper respiratory tract mucosa. For this reason, egg liquor is based on the principle described above, but only works for very early colds.
上気道粘膜に軽い痛みを覚える程度の高濃度のメントール蒸気を徐放的に 吸入すると、 高熱は 1 日で下がるが、 3 7度 C前半の微熱が数日続く ことが ある。  Slow-release inhalation of high-concentration menthol vapor that causes mild pain to the upper respiratory mucosa reduces the high fever in one day, but may cause a slight fever in the first half of 37 ° C for several days.

Claims

請求の範.顧 The scope of the claim
上気道粘膜細胞の生理機能を麻痺させる程度の濃度の薬剤を徐放 · 吸入して 風邪を根本治療し、 花粉症を時限的に治療する方法。  A method to gradually release and inhale a drug at a concentration enough to paralyze the physiology of the upper respiratory mucosal cells, to treat the common cold and timely treat hay fever.
PCT/JP2001/005225 2000-07-17 2001-06-19 Method of fundamentally treating common cold WO2002005802A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001274552A AU2001274552A1 (en) 2000-07-17 2001-06-19 Method of fundamentally treating common cold

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-250327 2000-07-17
JP2000250327A JP2002030000A (en) 2000-07-17 2000-07-17 Fundamental treatment for common cold

Publications (1)

Publication Number Publication Date
WO2002005802A1 true WO2002005802A1 (en) 2002-01-24

Family

ID=18739923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/005225 WO2002005802A1 (en) 2000-07-17 2001-06-19 Method of fundamentally treating common cold

Country Status (3)

Country Link
JP (1) JP2002030000A (en)
AU (1) AU2001274552A1 (en)
WO (1) WO2002005802A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037237A1 (en) * 2002-10-24 2004-05-06 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
EP2014333A1 (en) 2007-07-12 2009-01-14 Hakiman Shargh Research Company Use of cooling agents for treatment or prevention of lacrimation or eye burning
CN102397361A (en) * 2011-11-26 2012-04-04 苏州派腾生物医药科技有限公司 Preparation method of granules for treating cold and cough
US10392371B2 (en) 2015-10-01 2019-08-27 Senomyx, Inc. Compounds useful as modulators of TRPM8
CN111419906A (en) * 2020-03-04 2020-07-17 柳保来 Medicament for treating neocoronary pneumonia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62101259A (en) * 1985-10-25 1987-05-11 安田　三郎 Cold treatment apparatus
JPS63209666A (en) * 1987-02-27 1988-08-31 帝三製薬株式会社 Menthol-containing mask
JPH01313062A (en) * 1988-06-14 1989-12-18 Kao Corp External remedy for cold
JPH07148280A (en) * 1993-10-04 1995-06-13 Koki Bussan Kk Mask
EP0893142A1 (en) * 1995-04-12 1999-01-27 Saburo Yasuda Mask for treating cold

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62101259A (en) * 1985-10-25 1987-05-11 安田　三郎 Cold treatment apparatus
JPS63209666A (en) * 1987-02-27 1988-08-31 帝三製薬株式会社 Menthol-containing mask
JPH01313062A (en) * 1988-06-14 1989-12-18 Kao Corp External remedy for cold
JPH07148280A (en) * 1993-10-04 1995-06-13 Koki Bussan Kk Mask
EP0893142A1 (en) * 1995-04-12 1999-01-27 Saburo Yasuda Mask for treating cold

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037237A1 (en) * 2002-10-24 2004-05-06 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
US7585890B2 (en) 2002-10-24 2009-09-08 Immunpharm A/S Pharmaceutical compositions comprising flavonoids and menthol
US7671086B2 (en) 2002-10-24 2010-03-02 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
EP2014333A1 (en) 2007-07-12 2009-01-14 Hakiman Shargh Research Company Use of cooling agents for treatment or prevention of lacrimation or eye burning
CN102397361A (en) * 2011-11-26 2012-04-04 苏州派腾生物医药科技有限公司 Preparation method of granules for treating cold and cough
US10392371B2 (en) 2015-10-01 2019-08-27 Senomyx, Inc. Compounds useful as modulators of TRPM8
CN111419906A (en) * 2020-03-04 2020-07-17 柳保来 Medicament for treating neocoronary pneumonia

Also Published As

Publication number Publication date
JP2002030000A (en) 2002-01-29
AU2001274552A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
BRPI0609725B8 (en) nebulizer filter device and system for aerosolizing a drug
JP6234899B2 (en) Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
RU2054180C1 (en) Method and aerosol for treating respiratory virus infections
WO2022111497A1 (en) Application of iodine in preparation of drugs for preventing and treating respiratory tract infectious diseases
CN108040468A (en) For treating oral cavity, throat and the preparation of breathing problem
WO2022199049A1 (en) Use of ulinastatin in preparation of drug for treating novel coronavirus pneumonia
WO2002005802A1 (en) Method of fundamentally treating common cold
JP7369523B2 (en) Treatment of moderate to severe influenza
RU2353376C1 (en) Method of bronchial pneumonia treatment and prevention in calves and piglets
CN106667974A (en) Preparation method of terbutaline sulfate solution for inhalation
RU2757360C1 (en) Use of a phospholipid emulsion containing an effective amount of dihydroquercetin, lecithin and glycine for the treatment of inflammatory diseases of the respiratory system
CN105412118B (en) Treat dyspneic Western medicine compound of acute and chronic and preparation method thereof
WO2022063320A1 (en) Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method
Tsang et al. H5N1 influenza pandemic: contingency plans
KR20190009294A (en) Carboxylic acids for treating / preventing nasal congestion
Arensman et al. Effects of small-particle aerosols of rimantadine and ribavirin on arterial blood pH and gas tensions and lung water content of A2 influenza-infected mice
US20220040098A1 (en) Methods for treating respiratory viral infections
EP3906934A1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
Waghchaure et al. A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT
US20220096407A1 (en) Composition for inhibiting respiratory viruses and respiratory virus prevention and treatment method
Susaman et al. Common Cold in Children 36
WO2022130031A1 (en) A pharmaceutical composition of nitazoxanide and mefloquine and method thereof
Liu Five supplementary therapies for COVID-19
WO2023083850A1 (en) Medicament for inhalation or breathing, and inhaler or breathing device comprising same
Jamshald Evidence for the cure of flu through nose breathing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase